In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
The index SPMO follows weights into stocks with the best 12-month performance, excluding the past month, adjusted for ...
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback